Free Trial Information
BioCentury | Jan 7, 2020
Company News

Jan. 6 Company Quick Takes: China approvals for AZ, Sanofi and Gene+; plus Apollomics-GlycoMimetics, Pfizer-Merck KGaA and more

...Trio of approvals from China’s NMPA China’s National Medical Products Administration approved NDAs for Lokelma sodium zirconium cyclosilicate...
Read More
BioCentury | Nov 19, 2019

Reducing ER stress through USP14 inhibition could treat diabetes

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Diabetes Targeting USP14 could treat Type II diabetes by reducing the effects of endoplasmic reticulum stress, which has been implicated in the disease’s pathogenesis. In lean mice, the ER stress inducer...
Read More
BioCentury | Aug 9, 2019
Company News

Allakos sustains its gains on strength of GI readout

Not even the dilution of an upsized follow-on offering could slow Allakos’ momentum as its share price marched north steadily through midweek on the strength of Phase II data in eosinophilic gastrointestinal disorders, suggesting investors...
Read More
BioCentury | Aug 5, 2019
Clinical News

Big gain for Allakos as first-in-class GI program heads toward pivotal phase

Allakos' management team has plenty of experience in M&A, and a new Phase II readout in eosinophilic GI disorders could provoke interest in the company as a Phase III-ready bolt-on acquisition target. Allakos Inc. (NASDAQ:ALLK)...
Read More
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...disease (ESRD) patients on hemodialysis Phase III data 4Q19 AstraZeneca plc (LSE:AZN; NYSE:AZN) Lokelma, sodium zirconium cyclosilicate (ZS-9...
Read More
BioCentury | Jun 19, 2019
Clinical News

June 19 Clinical Quick Takes: G1 jumps on breast cancer data; plus Linzess, Lokelma, Boehringer/OSE, GCAR and more

...doctors and patients think about treatment goals (see “Getting to the Point in IBS” ). Lokelma...
...said 41.2% of hyperkalemic end-stage renal disease patients on stable dialysis who received Lokelma sodium zirconium cyclosilicate (ZS-9...
...VEGFR-2 (KDR/Flk-1) - Vascular endothelial growth factor receptor 2 BioCentury Staff Constella, Linzess, linaclotide (ASP0456, MD-1100) Lokelma, sodium zirconium cyclosilicate (ZS-9) OSE-172...
Read More
BioCentury | Mar 28, 2019
Politics & Policy

China lists 30 more overseas drugs eligible for Priority Review

...SIX:ROG; OTCQX:RHHBY); HIV drug Biktarvy bictegravir/emtricitabine/tenofovir alafenamide from Gilead Sciences Inc. (NASDAQ:GILD); hyperkalemia drug Lokelma sodium zirconium cyclosilicate...
...ikervis, vekacia, verkazia) Erleada (Brand), JNJ56021927 (Compound #), ARN-509 (Compound #), apalutamide (Generic), Erleada (Other) Lokelma, sodium zirconium cyclosilicate (ZS-9) Xofluza...
Read More
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
Read More
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

...SDA approves Ganovo danoprevir to treat HCV AstraZeneca plc (LSE:AZN; NYSE:AZN) FDA approves Lokelma sodium zirconium cyclosilicate (ZS-9...
Read More
BioCentury | May 25, 2018
Clinical News

Third time's the charm for AZ hyperkalemia drug

...AstraZeneca plc (LSE:AZN; NYSE:AZN) said on May 18 that FDA approved Lokelma sodium zirconium cyclosilicate (ZS-9) to treat...
...sodium zirconium cyclosilicate (ZS-9) to treat hyperkalemia in adults. AZ had received two complete response letters for Lokelma...
...AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Product: Lokelma sodium zirconium cyclosilicate (ZS-9) Business: Hematology Elizabeth S. Eaton Lokelma, sodium zirconium cyclosilicate (ZS-9) AstraZeneca...
Read More
Items per page:
1 - 10 of 96